Efficacy of baricitinib in severe coronavirus disease 2019
Efficacy of baricitinib in severe coronavirus disease 2019
About this item
Full title
Author / Creator
Publisher
India: Medknow Publications & Media Pvt Ltd
Journal title
Language
English
Formats
Publication information
Publisher
India: Medknow Publications & Media Pvt Ltd
Subjects
More information
Scope and Contents
Contents
Abstract
Background
Coronavirus disease 2019 (COVID-19) binds to angiotensin-converting enzyme through a viral spike protein prompting an inflammatory cascade. Baricitinib, an oral drug, is a selective inhibitor of Janus kinase (JAK) 1 and 2 and interferes with the intracellular signaling pathway of many cytokines and in combination with remd...
Alternative Titles
Full title
Efficacy of baricitinib in severe coronavirus disease 2019
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7411154a40ed4a8c8d1f4d086f75da9c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7411154a40ed4a8c8d1f4d086f75da9c
Other Identifiers
ISSN
0422-7638
E-ISSN
2090-9950
DOI
10.4103/ecdt.ECDT_83_22
